相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis
Ming Yin et al.
CLINICAL CANCER RESEARCH (2011)
Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin
Michael A. Gordon et al.
PHARMACOGENOMICS (2011)
Large age and hospital-dependent variation in administration of adjuvant chemotherapy for stage III colon cancer in southern Netherlands
L. N. van Steenbergen et al.
ANNALS OF ONCOLOGY (2010)
Gender Disparities in Metastatic Colorectal Cancer Survival
Andrew Hendifar et al.
CLINICAL CANCER RESEARCH (2009)
Gender Influences Treatment and Survival in Colorectal Cancer Surgery
E. Carter Paulson et al.
DISEASES OF THE COLON & RECTUM (2009)
Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients
Dina M. Kweekel et al.
EUROPEAN JOURNAL OF CANCER (2009)
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes
Penelope A. Bradbury et al.
PHARMACOGENETICS AND GENOMICS (2009)
ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients:: A preliminary study
Ming-Yii Huang et al.
BMC CANCER (2008)
Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
L. Pare et al.
BRITISH JOURNAL OF CANCER (2008)
Platinum resistance: The role of DNA repair pathways
Lainie P. Martin et al.
CLINICAL CANCER RESEARCH (2008)
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07
J. Philip Kuebler et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
Annamaria Ruzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Molecular mechanisms of resistance and toxicity associated with platinating agents
Cara A. Rabik et al.
CANCER TREATMENT REVIEWS (2007)
Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer
Deirdre P. Cronin et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy
Miguel Quintela-Fandino et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Polymorphisms in genes of nucleotide and base excision repair:: Risk and prognosis of colorectal cancer
V Moreno et al.
CLINICAL CANCER RESEARCH (2006)
ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer
J Viguier et al.
CLINICAL CANCER RESEARCH (2005)
Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy
DM Kweekel et al.
CANCER TREATMENT REVIEWS (2005)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
XPD polymorphisms: effects on DNA repair proficiency
RM Lunn et al.
CARCINOGENESIS (2000)
分享论文
